38 Neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiation for squamous cell cancer of the esophagus — A preliminary analysis of intergroup trial 0122 (ECOG PE-289/RTOG 9012)

1995 ◽  
Vol 32 ◽  
pp. 160 ◽  
Author(s):  
B. Minsky ◽  
D. Neuberg ◽  
D. Kelsen ◽  
T. Pisansky ◽  
R. Ginsberg ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Squamous Cell ◽  
Preliminary Analysis ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Concurrent Chemotherapy ◽  
High Dose ◽  
Cancer Of The Esophagus ◽  
Intergroup Trial ◽  
Dose Radiation

scholarly journals Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
He-San Luo ◽  
He-Cheng Huang ◽  
Lian-Xing Lin
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Standard Dose ◽  
Meta Analysis ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
High Dose ◽  
Radiotherapy Techniques ◽  
Dose Radiation ◽  
Modern Radiotherapy

Abstract Background and objectives Radiation Therapy Oncology Group (RTOG) 94–05 has demonstrated that higher dose radiation didn’t improve outcome of patients with esophageal cancer (EC). However, several retrospective studies showed that a higher dose radiation based on modern radiotherapy techniques could improve overall survival (OS) and local control rate (LCR) of patients with EC, especially esophageal squamous cell cancer (ESCC). As trials have provided updated and controversial data, we performed this updated meta-analysis to investigate whether high-dose (> = 60 Gy) radiotherapy in definitive concurrent chemo-radiotherapy (CCRT) could yield benefit compared to standard dose radiotherapy. Methods A systematic literature search was carried out in the database of MEDLINE, PubMed and Embase. All studies published between 1 January 1990 and 31 December 2018 on the association between radiation dose and curative efficiency in EC were included in this meta-analysis. The hazard ratio (HR) was used to evaluate the time-to-event data employing RevMan version 5.3. Results Eight articles with a total of 3736 patients were finally included. Results indicated that there was a significant benefit in favor of high dose radiotherapy (HD-RT) regarding OS (HR = 0.78, 95%CI: 0.72–0.84, p < 0.001; 2-year OS risk ratio (RR) = 1.25, 95%CI: 1.14–1.37, p < 0.001), progression-free survival (PFS) (P = 0.001, HR = 0.7, 95%CI: 0.57–0.87) and LRFS (P < 0.001, HR = 0.52, 95%CI: 0.36–0.74) . Conclusions HD-RT (> = 60 Gy) based on modern radiotherapy techniques in definitive CCRT appears to improve OS, PFS amd LRFS compared to the SD-RT in patients with ESCC.

A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus

2007 ◽  
Vol 83 (2) ◽  
pp. 139-147 ◽  
Author(s):  
Shaleen Kumar ◽  
Kislay Dimri ◽  
Rohini Khurana ◽  
Neeraj Rastogi ◽  
Koilpillai Joseph Maria Das ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Randomised Trial ◽  
Cancer Of The Esophagus

MRI features in differentiating mucosal high-grade neoplasia from early invasive squamous cell cancer of the esophagus

2020 ◽  
Vol 30 (6) ◽  
pp. 3455-3461
Author(s):  
Jinrong Qu ◽  
Zhaoqi Wang ◽  
Jianjun Qin ◽  
Hongkai Zhang ◽  
Yan Zhao ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
High Grade ◽  
Mri Features ◽  
Cancer Of The Esophagus
Sign in / Sign up

Export Citation Format

Share Document